Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
5.52
+0.49 (9.74%)
At close: May 13, 2026, 4:00 PM EDT
5.51
-0.01 (-0.18%)
After-hours: May 13, 2026, 7:36 PM EDT
Passage Bio Employees
Passage Bio had 24 employees as of December 31, 2025. The number of employees decreased by 36 or -60.00% compared to the previous year.
Employees
24
Change (1Y)
-36
Growth (1Y)
-60.00%
Revenue / Employee
n/a
Profits / Employee
-$1,569,833
Market Cap
17.71M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 24 | -36 | -60.00% |
| Dec 31, 2024 | 60 | 2 | 3.45% |
| Dec 31, 2023 | 58 | -27 | -31.76% |
| Dec 31, 2022 | 85 | -48 | -36.09% |
| Dec 31, 2021 | 133 | 59 | 79.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioLineRx | 24 |
| Moleculin Biotech | 17 |
| Theriva Biologics | 16 |
| NewcelX | 15 |
| Cellectar Biosciences | 11 |
| Genenta Science | 9 |
| Lexaria Bioscience | 7 |
| Intensity Therapeutics | 7 |
PASG News
- 22 days ago - Wedbush downgrades Passage Bio to Neutral on regulatory uncertainties - TheFly
- 22 days ago - Passage Bio downgraded to Hold from Buy at TD Cowen - TheFly
- 22 days ago - Passage Bio price target lowered to $15 from $30 at Oppenheimer - TheFly
- 22 days ago - Passage Bio downgraded to Neutral from Outperform at Wedbush - TheFly
- 22 days ago - Passage Bio downgraded to Neutral from Buy at Chardan - TheFly
- 23 days ago - Passage Bio downgraded to Neutral from Buy at Lucid Capital - TheFly
- 23 days ago - Passage Bio reports updated interim data from upliFT-D trial - TheFly
- 23 days ago - Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates - GlobeNewsWire